Bayesian Capital Management, LP Syndax Pharmaceuticals Inc Transaction History

Bayesian Capital Management, LP

  • $838 Million
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$11.39 - $21.67 $172,171 - $327,563
15,116 New
15,116 $326,000
Q2 2023

Aug 14, 2023
SELL
$19.35 - $22.31 $19,253 - $22,198
-995 Reduced 5.33%
17,669 $369,000
Q1 2023

May 15, 2023
SELL
$20.66 - $28.98 $35,122 - $49,266
-1,700 Reduced 8.35%
18,664 $394,000
Q4 2022

Feb 14, 2023
BUY
$20.64 - $26.24 $195,811 - $248,938
9,487 Added 87.22%
20,364 $518,000
Q3 2022

Nov 14, 2022
BUY
$18.51 - $24.79 $201,333 - $269,640
10,877 New
10,877 $261,000

Others Institutions Holding SNDX

# of Institutions
228
Shares Held
88.4M
Call Options Held
1.01M
Put Options Held
692K
View Full List

About Syndax Pharmaceuticals Inc

SNDX Quotes by TradingView
  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $796M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email